KMT2A and breast cancer: Bliss and Loewe algorithms separately defined the combination of low-dose PI3K and MLL1 inhibition as synergistic; synergy was not achieved for the normal breast cell line MCF10A or the PI3K wildtype, HR+ breast cancer cell line HCC1500 (Fig. 4C; ref. 21).